CLSDQ — Clearside Biomedical Income Statement
0.000.00%
Last trade - 00:00- $4.50m
- -$2.30m
- $1.66m
- 21
- 29
- 16
- 10
Annual income statement for Clearside Biomedical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 7.89 | 29.6 | 1.33 | 8.23 | 1.66 |
| Cost of Revenue | |||||
| Gross Profit | — | — | 1.12 | 7.87 | 1.51 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 25.8 | 29.2 | 30.9 | 31.4 | 29.1 |
| Operating Profit | -17.9 | 0.376 | -29.6 | -23.1 | -27.4 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -18.2 | 0.376 | -32.9 | -32.5 | -34.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -18.2 | 0.376 | -32.9 | -32.5 | -34.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -18.2 | 0.376 | -32.9 | -32.5 | -34.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18.2 | 0.376 | -32.9 | -32.5 | -34.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.87 | -0.157 | -8.37 | -8.3 | -7.28 |